| ARDELYX INC. DL-,0001 |
| USA |
| Gesundheit |
| US0396971071 / A116X0 |
| 41X (Frankfurt) / ARDX (NASDAQ) |
| FRA:41X, ETR:41X, 41X:GR, NASDAQ:ARDX |
| - |
| https://ardelyx.com/ |
|
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA ..
>Volltext.. |
| 682.09 Mio. EUR |
| 656.34 Mio. EUR |
| 422.09 Mio. EUR |
| -29.78 Mio. EUR |
| -50.01 Mio. EUR |
| -0.2 EUR |
| 231.09 Mio. EUR |
| 41.75 Mio. EUR |
| -13.99 Mio. EUR |
| 2.23 |
| 21.79% |
| -1.61% |
| - |
| - |
| - |
| - |
| ARDELYX |
| 12.11.26 |
|
||||
|
||||
|